tiprankstipranks
Advertisement
Advertisement

KTTA Stock Latest News

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA
The FlyPasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA
1d ago
KTTA
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
PremiumThe Fly
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
5d ago
KTTA
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained
PremiumRatings
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained
13d ago
KTTA
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
PremiumCompany Announcements
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives
30d ago
8K
KTTA
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
PremiumThe Fly
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
1M ago
KTTA
Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004
PremiumThe FlyPasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004
1M ago
KTTA
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
Premium
Company Announcements
Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice
3M ago
8K
KTTA
Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization
Premium
Company Announcements
Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization
4M ago
8K
KTTA
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway
PremiumRatings
Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway
5M ago
KTTA
Pasithea Therapeutics provides updated timeline on PAS-004 programs
PremiumThe Fly
Pasithea Therapeutics provides updated timeline on PAS-004 programs
5M ago
KTTA
Pasithea Therapeutics Regains Nasdaq Compliance
PremiumCompany Announcements
Pasithea Therapeutics Regains Nasdaq Compliance
6M ago
8K
KTTA
Pasithea Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Pasithea Therapeutics initiated with a Buy at H.C. Wainwright
6M ago
KTTA
3 Penny Stocks to Watch Now, 12/2/25
PremiumMarket News3 Penny Stocks to Watch Now, 12/2/25
6M ago
ADTX
BEAM
Pasithea Therapeutics Completes $60M Public Offering
Premium
Company Announcements
Pasithea Therapeutics Completes $60M Public Offering
6M ago
8K
KTTA
Pasithea Therapeutics prices 80M shares at 75c in public offering
Premium
The Fly
Pasithea Therapeutics prices 80M shares at 75c in public offering
6M ago
KTTA
3 Penny Stocks to Watch Now, 11/27/25
PremiumMarket News
3 Penny Stocks to Watch Now, 11/27/25
6M ago
AMBR
KTTA
Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004
PremiumCompany Announcements
Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004
6M ago
8K
KTTA
Pasithea Therapeutics announces $1M award by ALS Association
PremiumThe Fly
Pasithea Therapeutics announces $1M award by ALS Association
6M ago
KTTA
Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004
PremiumThe Fly
Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004
6M ago
KTTA
Pasithea says tablet PK exposure increases proprtionally with dose increase
PremiumThe FlyPasithea says tablet PK exposure increases proprtionally with dose increase
6M ago
KTTA
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
6M ago
C
HD
Why Is Pasithea Therapeutics Stock (KTTA) Down Today?
Premium
Market News
Why Is Pasithea Therapeutics Stock (KTTA) Down Today?
6M ago
KTTA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >